122 related articles for article (PubMed ID: 38094390)
1. Retracted: Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9839167. PubMed ID: 38094390
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer.
Tang Q; Liang Z; Zhou Y; Huang Y
Comput Math Methods Med; 2022; 2022():8542376. PubMed ID: 35309830
[TBL] [Abstract][Full Text] [Related]
3. [Levels of tPSA and fPSA and count of peripheral blood neutrophils in the diagnosis of prostate cancer].
Zhang SQ; Su Q
Zhonghua Nan Ke Xue; 2022 Dec; 28(12):1089-1095. PubMed ID: 37846628
[TBL] [Abstract][Full Text] [Related]
4. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
6. The establishment and evaluation of a new model for the prediction of prostate cancer.
Wang Q; Li YF; Jiang J; Zhang Y; Liu XD; Li K
Medicine (Baltimore); 2017 Mar; 96(11):e6138. PubMed ID: 28296726
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of the ratio of free prostate specific antigen to total prostate specific antigen.
Dalva I; Akan H; Yildiz O; Telli C; Bingol N
Int Urol Nephrol; 1999; 31(5):675-80. PubMed ID: 10755359
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
Kapoor N; Jain R; Surange S; Bhardwaj VK; Srivastava A
Indian J Pathol Microbiol; 2006 Apr; 49(2):178-81. PubMed ID: 16933710
[TBL] [Abstract][Full Text] [Related]
9. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).
Martin BJ; Finlay JA; Sterling K; Ward M; Lifsey D; Mercante D; Jainto JM; Martin L; Rayford W
Prostate Cancer Prostatic Dis; 2004; 7(2):132-7. PubMed ID: 15007379
[TBL] [Abstract][Full Text] [Related]
10. Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer.
Stimac G; Spajic B; Reljic A; Katusic J; Popovic A; Grubisic I; Tomas D
Korean J Urol; 2014 Aug; 55(8):527-32. PubMed ID: 25132947
[TBL] [Abstract][Full Text] [Related]
11. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
[TBL] [Abstract][Full Text] [Related]
13. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
[TBL] [Abstract][Full Text] [Related]
14. Use of various combinations of free, complexed and total prostate-specific antigen levels as predictors of the pathologic stage of prostate cancer.
Okegawa T; Noda H; Ohta M; Kato M; Nutahara K; Higashihara E
Int J Urol; 2001 Aug; 8(8):438-43. PubMed ID: 11555010
[TBL] [Abstract][Full Text] [Related]
15. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
16. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
17. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
18. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
19. [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer].
Mazo EB; Sergeeva NA; Grigor'ev ME; Lebedev DV; Solov'eva EV; Konorev VA; Krovets AA
Urologiia; 2006; (3):21-4. PubMed ID: 16889084
[TBL] [Abstract][Full Text] [Related]
20. [The application of complexed PSA and its relative indexes in the diagnosis of prostate cancer].
Chen ZH; Zhao J; Wu JM; Xiao CG
Zhonghua Nan Ke Xue; 2003 Feb; 9(1):36-9. PubMed ID: 12680329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
